| pubmed-article:18004569 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18004569 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:18004569 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:18004569 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:18004569 | lifeskim:mentions | umls-concept:C0935989 | lld:lifeskim |
| pubmed-article:18004569 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:18004569 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:18004569 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18004569 | pubmed:dateCreated | 2008-7-16 | lld:pubmed |
| pubmed-article:18004569 | pubmed:abstractText | We investigated the potential drug-drug interaction between imatinib and fludarabine, which may be concomitantly administered in chronic myeloid leukemia (CML) patients receiving fludarabine-based conditioning for allogeneic hematopoietic cell transplantation (HCT). Imatinib is an inhibitor of human equilibrative transporters (hENTs), which are responsible for the intracellular uptake of fludarabine. | lld:pubmed |
| pubmed-article:18004569 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18004569 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18004569 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18004569 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18004569 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:18004569 | pubmed:author | pubmed-author:McCuneJeannin... | lld:pubmed |
| pubmed-article:18004569 | pubmed:author | pubmed-author:HeimfeldShell... | lld:pubmed |
| pubmed-article:18004569 | pubmed:author | pubmed-author:WangJoanneJ | lld:pubmed |
| pubmed-article:18004569 | pubmed:author | pubmed-author:WoodahlErica... | lld:pubmed |
| pubmed-article:18004569 | pubmed:author | pubmed-author:RenAaron GAG | lld:pubmed |
| pubmed-article:18004569 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18004569 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:18004569 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18004569 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18004569 | pubmed:pagination | 735-9 | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:meshHeading | pubmed-meshheading:18004569... | lld:pubmed |
| pubmed-article:18004569 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18004569 | pubmed:articleTitle | Imatinib inhibition of fludarabine uptake in T-lymphocytes. | lld:pubmed |
| pubmed-article:18004569 | pubmed:affiliation | Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA. | lld:pubmed |
| pubmed-article:18004569 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18004569 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:18004569 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18004569 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
